MeiraGTx Holdings plc 8-K

What Happened

• On April 15, 2026 MeiraGTx Holdings plc and its subsidiary MeiraGTx Ocular UK Limited closed an Asset Purchase Agreement with Janssen Pharmaceuticals to acquire rights and related assets under the UCL License Agreement for a gene therapy targeting X‑linked retinitis pigmentosa (RPGR product).
• Purchase consideration: $25,000,000 upfront in cash; a one‑time contingent payment of $50,000,000 payable if (i) U.S. regulatory approval is obtained for an RPGR product and (ii) U.S. cumulative net sales after closing first exceed $250,000,000. MeiraGTx will also pay global royalties in the mid‑teens percent of annual net sales beginning on or after July 1, 2029.
• The agreement grants MeiraGTx a non‑exclusive, perpetual worldwide license to certain Janssen know‑how and patents needed to exploit the RPGR product (with sublicensing rights) and includes customary indemnities and a five‑year employee non‑solicitation covenant. JJDC (Johnson & Johnson’s venture arm), which owns more than 5% of MeiraGTx, agreed to a 12‑month lock‑up on selling MeiraGTx shares.

Key Details

• Closing date: April 15, 2026. Press release issued April 16, 2026.
• Upfront cash: $25,000,000; contingent milestone: $50,000,000 tied to U.S. approval + >$250M U.S. sales.
• Royalties: mid‑teens percentage of annual net sales globally, payable starting on/after July 1, 2029.
• Clinical update included: Janssen data showed the primary Visual Mobility Assessment did not reach statistical significance but showed positive trends; significant improvements observed on several retinal and visual function measures; safety profile as expected.
• Separate corporate update: Amendment to Hologen transactions (April 2, 2026) — MeiraGTx to receive 250,000 Class A Hologen shares and revised completion and funding mechanics that adjust share purchases and ownership percentages in related joint ventures.

Why It Matters

• This deal adds an RPGR gene therapy program to MeiraGTx’s portfolio with defined near‑term cash commitments ($25M upfront) and potential sizable future payments and royalties, aligning future payouts with development/regulatory success and commercial sales.
• The filing provides clinical context: while the primary functional endpoint missed significance, other efficacy signals and manageable safety were reported, meaning development and regulatory risks remain material.
• Financially, investors should note the contingent and royalty obligations (which will reduce future margin on the asset) and the JJDC lock‑up that temporarily limits insider share sales. The Hologen amendments also affect MeiraGTx’s collaborations and expected upfront funding under earlier framework agreements.